Articles tagged with Tumor Cells
Lung adenocarcinoma cells manipulate macrophage lipid metabolism to drive tumor progression. This exploitation of immune cells' metabolic pathways may be targeted with statins, improving lung cancer treatments.
Researchers discovered that immune cells called natural killer cells rapidly lose their functionality when entering solid tumours, adopting a dormant state. However, targeting the IL-15 pathway can restore NK cell activity and improve tumor control. This breakthrough could pave the way for new cancer treatments.
Researchers have developed a synergistic antitumor drug that activates calcium channels in tumor cells, leading to a deadly influx of calcium ions. The treatment involves using a bioactive agent to generate reactive oxygen species, which triggers the activation of calcium channels in both the outer membrane and endoplasmic reticulum.
A new cancer GPS method uses a water-soluble, luminescent europium complex to evaluate the malignancy grade of model glioma tumor cells without causing harm. The method measures changes in the lifetime of the complex's red-light emission, revealing differences in tumor activity and growth processes between different malignancy grades.
A team of researchers created a 3D bioprinted brain blood vessel model to investigate the impact of blood vessel curvature on metastatic cancer development. The model revealed that increased blood vessel curvature correlates with heightened cancer cell adherence and extravasation.
Researchers aim to improve glioma treatment with direct light therapy that targets cancer cells without harming healthy ones. The project will investigate the efficacy and safety of this approach, potentially leading to improved treatment outcomes.
A study by the University of Sheffield found that breast cancer cells take advantage of nutrients in the extracellular matrix when faced with nutrient starvation. The cells use an ingestion process called macropinocytosis to consume the matrix, breaking it down into energy-releasing substrates.
Breast cancer cells survive by consuming the extracellular matrix when nutrients are scarce. The process involves macropinocytosis and metabolic conversion of key amino acids to energy-releasing substrates. This mechanism could represent a novel therapeutic target.
A team of scientists has identified a previously unrecognized control point in DNA repair processes, which could lead to novel cancer therapies by inhibiting the repair of damaged cancer cells. The newly discovered GSE1-CoREST complex contains three enzymes that control DNA repair and may form the basis for improved cancer treatments.
Researchers at UMass Amherst have discovered that tumor cells outwit the body's immune system by incorporating cytoplasmic material into their own T cells. This 'mosquito effect' helps cancerous tumors evade the immune system, making it a promising area of study for developing more effective treatments.
A new MRI-based method uses CEST technology to detect water cycling across cellular membranes, providing a non-invasive way to assess tumor malignancy and treatment effectiveness. The technique sheds light on tumor phenotype and offers a promising tool for personalized cancer diagnosis and therapy.
Researchers have identified promising treatment candidates for morphine tolerance and cancer, as well as a biomarker for kidney injury. A monoclonal antibody targeting the mu-opioid receptor has been shown to alleviate morphine tolerance and physical dependence, while inducing excessive mitochondrial fission in tumor cells. Additionall...
Researchers have decoded the factor driving rapid growth of T cell lymphomas, revealing a 'sugar appetite' that triggers processes leading to tumor growth. The discovery provides new hope for treating aggressive cancer types, with existing medications potentially effective against these tumors.
A study by the University of the Basque Country uses game theory to establish that tumours with less cellular heterogeneity are more aggressive. The work suggests a fresh theoretical approach for new therapeutic strategies, focusing on preserving high intratumour heterogeneity.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
Researchers found that tumor-resident T-cell receptor sequences showed high complementarity with the cancer testis antigen DDX53, suggesting an immune response that selects for DDX53-negative cells. This association was correlated with worse disease-free survival rates, highlighting a potential early esophageal cancer antigen.
Research reveals chromatin's role in preventing DNA-RNA hybrid formation, which causes genomic instability and cancer. DNA-RNA hybrids are a risk factor in tumour development, suggesting potential use as an indicator of carcinogenic risk.
Researchers developed nanoparticles to transport Gemcitabine directly into tumors, increasing efficacy and sparing healthy cells. The approach shows potential to treat pancreatic carcinomas more accurately and with reduced side effects.
Researchers at Purdue University have developed a novel cancer immunotherapy compound that targets the enzyme TC-PTP, found in both cancer cells and T cells. Deleting this enzyme promotes antigen presentation, alerting the immune system to tumor cells, while stimulating T-cell activation enhances their ability to fight and destroy tumors.
Researchers are exploring new ways to fight metastasis, including the use of bacteria to activate a defensive response against cancer. Stress and changes in circadian rhythms have also been linked to metastasis, suggesting that these factors may be targets for prevention or treatment.
A new AI method combines satellite imaging and ecological analysis techniques to interpret large amounts of data from tumor tissue, providing insights into how cancer works. This approach aims to tailor cancer treatments to individual needs and avoid unnecessary side effects.
A team of researchers at Kyoto University has found that a deficiency in the enzyme B4GALT3 inhibits tumor growth in mice. The study shows that reduced glycosylation on T cell surfaces correlates with increased CD8+ immune cells infiltrating tumors.
Researchers found that tumour cells escape immunotherapy by losing or changing BCMA and GPRC5D targets on their surface. This understanding has led to the suggestion of periodically profiling myeloma cells throughout a patient's treatment course to adapt treatment strategies.
Researchers are testing a single target to weaken tumors and strengthen immune cells in pediatric brain tumor patients. The goal is to improve the effectiveness of CAR-T therapy, which has shown promise but also leads to exhaustion of immune cells.
Researchers discovered a new role for extracellular signal-regulated kinase (ERK) in a pathway activated by interferon-gamma that leads to cancer cell death. Hyperactivation of ERK causes stress in cells, triggering cell death through specific proteins DR5 and NOXA.
Researchers identified a circulating tumor DNA (ctDNA) biomarker that can predict disease recurrence and response to treatment in patients with BRAF-negative melanoma. The study found that measuring ctDNA levels and variants can help tailor therapy and improve patient outcomes.
Researchers combined three highly potent cancer drugs in a single prodrug that is activated in tumor cells, resulting in improved efficacy and reduced side effects. The new approach has shown promise as a potential solution to reduce the burden on patients' bodies during cancer treatment.
Researchers at UMass Amherst have identified a small strand of microRNA called let-7 as crucial in governing the formation of cellular memories that enable T-cells to recognize and attack tumor cells. This discovery offers new insights into how vaccines work and could lead to improved cancer therapies by boosting cellular memory.
Researchers discovered that fine-tuning mitochondrial energy production reduces melanoma tumor growth and enhances immune response in mice. The study reveals that manipulating mitochondrial electron transport increases expression of immune genes and makes tumor cells more visible to killer T cells.
Researchers at the Swiss Cancer Center Léman have discovered a way to prolong the functionality of CAR-T cells, which are used against blood cancers. By inhibiting a specific metabolic mechanism, they created CAR-T cells with enhanced immune memory, capable of fighting tumour cells for longer.
A recent study from MIT found that measuring diversity of mutations within a tumor generates more accurate predictions of treatment success than overall mutation count. This discovery could help doctors identify patients who would benefit most from checkpoint blockade inhibitors.
New research from Cold Spring Harbor Laboratory suggests that high tumor mutation burden does not guarantee an effective immune response in patients with mismatch repair deficiency. The study found that tumors with identical mutations across all cells responded to immunotherapy, while those with subclonal mutations did not.
Researchers from Politecnico di Milano have discovered the early manifestation of therapy-induced senescence in human tumor cells. The study highlights the importance of non-invasive technologies in understanding cancer biology and paves the way for personalized treatments.
A new study presents a promising method for developing user-defined agents that can selectively target and destroy malignant cells. The agents, called programmable T-cell engagers (PTEs), are created with DNA origami and can be fitted with different antibodies to target specific tumor cells.
Glutamine metabolism plays a crucial role in cancer cell growth and survival, with its inhibition shown to block cancer cell growth in vivo and in vitro. A recent editorial paper suggests that glutamine dysregulation may also impact the tumor microenvironment, potentially leading to increased oxidative stress and cancer cell death.
Researchers find immunotherapy treatment anti-CTLA-4 leads to greater survival in mice with glioblastoma and discover new way cells kill cancer by triggering microglia, specialized immune cells in the brain. This breakthrough could lead to more effective treatments for human brain cancer.
Researchers identified a mechanism regulating tumor growth in the skeleton, which decreases with age and can result from hormonal changes or chemotherapy. Mineralization of bone matrix reduces tumor cell growth and promotes genes associated with better patient prognosis.
A new study improves the chances of finding the right drug to kill individual cancers in children by incorporating high-throughput drug screening into precision medicine. The approach reveals additional drug sensitivities and predicts clinical response, leading to better treatment options.
Researchers created a flexible and potent 'on-demand' whole tumor cell vaccine (TCV) that responds to near-infrared laser irradiation, boosting the immune response and effectively suppressing tumor growth. The TCV was tested in various murine xenograft models and showed promising therapeutic efficacy.
A breakthrough treatment targeting bone marrow cancer cells destroyed 90% of multiple myeloma cells in laboratory tests and 60% in human tissue samples. Researchers developed lipid-based nanoparticles containing RNA molecules that silence the CKAP5 gene, inhibiting cancer cell division.
Researchers at NUS developed a new photodynamic therapy that selectively kills breast cancer cells without damaging surrounding tissues. The treatment uses a biocompatible silicone implant loaded with nanoparticles activated by near-infrared light, reducing the risk of toxicity and improving tumour control.
Research reveals NADPH's crucial role in accurate chromosome segregation and genomic integrity in aneuploid tumor cells. The study identifies potential targets for novel therapies by intervening in metabolic pathways, providing new biomarkers for selective inhibition of aneuploid tumors.
Researchers at Tokyo Institute of Technology developed a novel boron agent that selectively accumulates in brain tumor cells, exhibits enhanced blood retention, and can be administered at low doses. The agent, PBC-IP, shows promising results in preclinical studies, highlighting its potential for radiotherapy in treating glioblastoma.
A novel biomaterials-based approach enhances adoptive T cell therapy with cancer vaccine technology, providing strong and long-lasting effects against solid tumors. In mice carrying melanomas, SIVET enables fast tumor shrinking and long-term protection.
Research suggests that glioblastoma cells possess large-scale coordination, allowing them to respond unison to therapies. Disrupting this organization may result in more powerful treatments for brain tumors.
The study investigates the effects of DPDT on human colon cancer HCT116 cells and non-tumorigenic MRC5 fibroblasts. The results show that DPDT preferentially targets HCT116 cells, inducing apoptosis and G2/M cell cycle arrest, likely through DNA topoisomerase I poisoning.
Researchers at Aarhus University have discovered a new method to activate the complement system using bispecific single-domain antibodies, termed BiCEs. These molecules can specifically target cancer cells and activate the complement system, leading to the killing of targeted cancer cells.
Researchers have developed a new approach to treating tumors using 'self-immolative' polyferrocenes that trigger a fatal cycle of oxidative stress in cancer cells. In experiments, these copolymers inhibited tumor growth with negligible side effects, offering potential for chemodynamic therapy.
Scientists from Institut Pasteur and Inserm discovered that CD4 T cells can remotely neutralize tumor cells by producing interferon gamma, offering new hopes for patients with incomplete responses to CAR T cell therapy. This study raises the possibility of personalized treatment approaches using larger quantities of CD4 CAR T cells.
A team of researchers found that a hydrogen sulfide donor adjuvant can disrupt mitochondrial respiration, suppressing heat shock protein production and making tumor cells more sensitive to photothermal therapy. This approach led to the eradication of tumors in laboratory mice with breast tumors within just a few days.
Researchers discovered that melanoma skin cancer cells adopt an efficient style of movement called rounded-amoeboid migration, which requires less energy than traditional cell movement. This process involves reshaping mitochondria to operate in a low-power mode, allowing cells to survive in stressful environments.
A research team at Göttingen University has discovered that mobile and stationary cells have different mechanical properties due to their cytoskeleton. The study found that intermediate filaments, which are crucial for cell stability, exhibit metal-like plasticity when stretched, similar to non-biological materials.
Researchers discovered that FDA-approved HDAC-inhibitors can impact energy metabolism in solid tumor cells, including glioblastoma. The combination of HDAC-inhibitors and imipridones may synergize to enhance killing of GBM cells by reversing cellular respiration.
Researchers from China explore the mechanisms of action and clinical data of bispecific antibodies, which have shown promise in increasing cytotoxicity against cancerous cells and enhancing immune response towards tumor clearance. Several bsAbs are being evaluated in phase I-III clinical trials for lung cancer treatment.
A team of researchers is exploring the potential of HDAC inhibitors to treat sickle cell disease by reactivating the fetal hemoglobin gene. Early evidence suggests that panobinostat, a specific inhibitor, can increase fetal hemoglobin levels in red blood cells and mouse models.
Research reveals that brain tumor cells communicate with astrocytes through microtubes, transferring mitochondria to enhance growth. This connection increases treatment resistance and tumorigenicity in glioblastoma tumors.
A clinical trial of 406 patients found that a fluorescent agent allowed surgeons to identify and remove residual tumor tissue with favorable results. The technique showed promising results in detecting tumor tissue missed by standard lumpectomy procedures, potentially avoiding second surgeries for positive margins.
Researchers developed glass filters to capture tumor cells from blood samples, enabling more efficient culture of these cells. The optimized filter design enhances the accuracy of cancer detection, allowing for earlier treatment and improved patient health.
A novel cell signaling pathway has been identified that could be targeted to treat aggressive pancreatic cancers. The High Mobility Group A1 (HMGA1) protein functions as a 'molecular switch' that activates genes required for tumor growth and invasion. Silencing HMGA1 or disrupting FGF19 signals in mouse models resulted in decreased tum...
A study of 5,000 patients with breast cancer found that women from disadvantaged neighborhoods had shorter breast cancer-specific survival rates compared to those from advantaged areas. The findings suggest potential unaccounted mechanisms, including social determinants of health and access to care.